A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
Phase of Trial: Phase III
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary) ; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.
- 05 Mar 2018 Planned End Date changed from 7 Apr 2019 to 3 Jun 2019.
- 05 Mar 2018 Planned primary completion date changed from 7 Apr 2019 to 3 Jun 2019.
- 02 May 2017 Planned number of patients changed from 3155 to 2980.